-
Electronic (PDF)
-
Site License
-
Enterprisewide
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - October 2010
GlobalData, October 2010, Pages: 68
Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - October 2010
Summary
Our “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – October 2010” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in September 2010. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.
Data presented in this report is derived from Our proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research."
Scope
- Analysis of the market trends for the pharmaceutical industry in the global arena.
- Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
- Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
- Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
- Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
- Analysis of partnership and licensing deals based on clinical stage of development of products.
- Summary of the pharmaceutical deals globally in the last six months.
- Information on the top deals happened in the pharmaceutical industry.
- Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
- League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.
Reasons to buy
- Enhance your decision making capability in a more rapid and time sensitive manner.
- Find out the major deal performing segments for investments in your industry.
- Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
- Identify companies that are aggressively looking to raise capital in the market
- Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
- Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
- Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
- Identify growth segments and opportunities in each region within the industry.
- Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
1
1.1 List of Tables
1.2 List of Figures
2 Deal Summary
2.1 Pharmaceuticals & Healthcare, Global Deals Analysis, September 2010
2.2 Pharmaceuticals & Healthcare, Global, Top Deals, September 2010
2.2.1 Johnson & Johnson To Acquire Additional Stake In Crucell
2.2.2 Covance Enters Into An Agreement With Sanofi-Aventis
2.2.3 Amgen Announces Debt Offering Of $1.5 Billion
2.2.4 Endo Pharmaceuticals To Acquire Qualitest Pharmaceuticals
2.2.5 Valeant Pharmaceuticals Prices Debt Offering Of $1.2 Billion
2.3 Pharmaceuticals and Healthcare, Global, by Type, Number of Deals and Deal Value, September 2010
3 Pharmaceuticals and Healthcare, Deals Summary, by Type
3.1 Pharmaceuticals and Healthcare, Global, M&A, September 2010
3.1.1 Top M&A Deals in September 2010
3.1.2 Pharmaceuticals and Healthcare, Global M&A Deals by Therapy Area, April 2010 – September 2010
3.2 Pharmaceuticals and Healthcare, Global, Equity Offering Deals, September 2010
3.2.1 Top Equity Offering Deals in September 2010
3.2.2 Pharmaceuticals and Healthcare, Global, Equity Offering Deals by Therapy Area, April 2010 – September 2010
3.3 Pharmaceuticals and Healthcare, Global, Debt Offering Deals, September 2010
3.3.1 Top Debt Offering Deals in September 2010
3.3.2 Pharmaceuticals and Healthcare, Global, Debt Offering Deals, by Therapy Area, April 2010 – September 2010
3.4 Pharmaceuticals and Healthcare, Global, Private Equity and Venture Capital Deals, September 2010
3.4.1 Top PE/VC Deals in September 2010
3.4.2 Pharmaceuticals and Healthcare, Global, PE/VC by Therapy Area, September 2010
3.4.3 Pharmaceuticals and Healthcare, Global, Venture Capital Deals by Stage of Financing, September 2010
3.4.4 Pharmaceuticals and Healthcare, Global, Top Venture Financing Firms, April 2010 – September 2010
3.4.5 Pharmaceuticals and Healthcare, Global, Top VC Backed Companies, April 2010 – September 2010
4 Pharmaceuticals and Healthcare, Global, Partnership Deals, September 2010
4.1 Pharmaceuticals and Healthcare, Global, Partnership Deals, September 2010
4.2 Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, April 2010 – September 2010
4.3 Pharmaceuticals and Healthcare, Global, Partnership Deals by Upfront and Milestone Payments and Deal Value (US$m), September 2010
4.3.1 Pharmaceuticals and Healthcare, Global, Top Partnership Deals by Payment Mode, September 2010
4.4 Pharmaceuticals and Healthcare, Global, Partnership Deals by Therapy Area, by Upfront and Milestone Payment and Deal Value (US$m), April 2010 – September 2010
4.5 Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, Number Of Deals and Deal Value (US$m), April 2010 – September 2010
4.6 Pharmaceuticals and Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payment and Deal Value (US$m), April 2010 – September 2010
5 Pharmaceuticals and Healthcare, Global, Licensing Agreements, September 2010
5.1 Pharmaceuticals and Healthcare, Global, Licensing Agreements, September 2010
5.2 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payment and Deal Value (US$m), September 2010
5.2.1 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements by Deal Value, September 2010
5.2.2 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements, by Total Upfront Payment, September 2010
5.2.3 Pharmaceuticals and Healthcare, Global, Top Licensing Agreements by Total Milestone Payment, September 2010
5.3 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Total Deal Value (US$m), April 2010 – September 2010
5.4 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront Payment and Milestone Payment (US$m), April 2010 – September 2010
5.5 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, Total Deal Value (US$m), April 2010 – September 2010
5.6 Pharmaceuticals and Healthcare, Global, Licensing Agreement Deals by Phase, Upfront Payment and Milestone Payment (US$m), April 2010 – September 2010
6 Deal Summary by Therapy Area
6.1 Pharmaceuticals and Healthcare, Oncology Deals, September 2010
6.1.1 Oncology – Deals of the Month
6.2 Pharmaceuticals and Healthcare, Central Nervous System Deals, September 2010
6.2.1 Central Nervous System – Deals of the Month
6.3 Pharmaceuticals and Healthcare, Immunology Deals, September 2010
6.3.1 Immunology – Deals of the Month
6.4 Pharmaceuticals and Healthcare, Infectious Disease Deals, September 2010
6.4.1 Infectious Diseases – Deals of the Month
6.5 Pharmaceuticals and Healthcare, Cardiovascular Deals, September 2010
6.5.1 Cardiovascular – Deals of the Month
6.6 Pharmaceuticals and Healthcare, Metabolic Disorders Deals, September 2010
6.6.1 Metabolic Disorders – Deals of the Month
6.7 Pharmaceuticals and Healthcare, Dermatology Deals, September 2010
6.7.1 Dermatology – Deals of the Month
7 Deal Summary by Geography
7.1 Pharmaceuticals and Healthcare, North America Region Deals, September 2010
7.1.1 North America – Deals of the Month
7.2 Pharmaceuticals and Healthcare, Europe Region Deals, September 2010
7.2.1 Europe – Deals of the Month
7.3 Pharmaceuticals and Healthcare, Asia-Pacific Deals, September 2010
7.3.1 Asia-Pacific – Deals of the Month
7.4 Pharmaceuticals and Healthcare, Rest of the World Deals, September 2010
7.4.1 Rest of the World – Deals of the Month
8 Pharmaceuticals and Healthcare, Top Advisors
8.1 Pharmaceuticals and Healthcare, Global Top Financial Advisors, M&A, April 2010 – September 2010
8.2 Pharmaceuticals and Healthcare, Top Financial Advisors, Equity Offerings, April 2010 – September 2010
9 Further Information
9.1 Methodology
9.2 About Us
9.3 Contact Us
9.4 Disclosure information
9.5 Disclaimer
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
